Payne, Katherine
Katherine Payne
VIAF ID: 270806230 (Personal)
Permalink: http://viaf.org/viaf/270806230
Preferred Forms
- 100 0 _ ‡a Katherine Payne
- 100 1 _ ‡a Payne, Katherine
- 100 1 _ ‡a Payne, Katherine
-
-
- 100 1 _ ‡a Payne, Katherine
4xx's: Alternate Name Forms (3)
Works
Title | Sources |
---|---|
Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? | |
The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation | |
Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost-efficacy analysis | |
The Cost-Effectiveness of a Pharmacogenetic Test: A Trial-Based Evaluation of TPMT Genotyping for Azathioprine | |
Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model. | |
Costing day case anesthesia: obtaining accurate patient-based costs for adults and children. | |
Critical points for an accurate human genome analysis. | |
Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. | |
Delivering a pharmacogenetic service: is there a role for genetic counselors? | |
Delivering health care through community pharmacies: are working conditions deterring female pharmacists' participation? | |
Developing national guidance on genetic testing for breast cancer predisposition: the role of economic evidence? | |
Do Pills Have No Ills? Capturing the Impact of Direct Treatment Disutility | |
Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines | |
The economic case for precision medicine. | |
Economic evaluations of personalized medicine: existing challenges and current developments | |
Economic Theory and Self-Reported Measures of Presenteeism in Musculoskeletal Disease | |
Economics of stratified medicine in rheumatoid arthritis | |
The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review | |
The emotional effects of genetic diseases: Implications for clinical genetics | |
Essentials of economic evaluation in healthcare , 2004 | |
Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis. | |
Exploring the feasibility of delivering standardized genomic care using ophthalmology as an example | |
Fish and chips all round? Regulation of DNA-based genetic diagnostics | |
Getting a diagnosis v. learning to live with it? The case of the progressive ataxias. | |
The impact of increasing workloads and role expansion on female community pharmacists in the United Kingdom | |
Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain | |
Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models. | |
Interventions to improve patient access to and utilisation of genetic and genomic counselling services | |
Investigating the Heterogeneity in Women’s Preferences for Breast Screening: Does the Communication of Risk Matter? | |
Is pelvic vein incompetence associated with symptoms of chronic pelvic pain in women? A pilot study. | |
The management of Otitis Media with Effusion in children with cleft palate (mOMEnt): a feasibility study and economic evaluation. | |
A model-based cost-effectiveness analysis of a grommets-led care pathway for children with cleft palate affected by otitis media with effusion | |
Outcome measurement in clinical genetics services: a systematic review of validated measures. | |
Parental and societal values for the risks and benefits of childhood combination vaccines | |
Patient empowerment: the need to consider it as a measurable patient-reported outcome for chronic conditions | |
Pharmacogenetics, the next challenge for pharmacy? | |
A Picture is Worth a Thousand Words: The Role of Survey Training Materials in Stated-Preference Studies | |
Power of gentleness : meditations on the risk of living | |
A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. | |
Propofol and halothane versus sevoflurane in paediatric day-case surgery: induction and recovery characteristics | |
Provision of information about newborn screening antenatally: a sequential exploratory mixed-methods project. | |
Puissance de la douceur. | |
Quantifying the Relationship between Capability and Health in Older People: Can't Map, Won't Map. | |
Reflections on market access for personalized medicine: recommendations for Europe | |
Reply: Guesstimates are not good enough for determining what is happening in routine care. | |
Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations | |
Risk as an attribute in discrete choice experiments: a systematic review of the literature. | |
The Role of Information Provision in Economic Evaluations of Newborn Bloodspot Screening: A Systematic Review | |
The Role of Qualitative Research Methods in Discrete Choice Experiments | |
Scale Heterogeneity in Healthcare Discrete Choice Experiments: A Primer. | |
Stratified medicine: a call for action | |
Study Comparing Vein Integrity and Clinical Outcomes in Open Vein Harvesting and 2 Types of Endoscopic Vein Harvesting for Coronary Artery Bypass Grafting: The VICO Randomized Clinical Trial (Vein Integrity and Clinical Outcomes). | |
Survival estimates stratified by the Nottingham Prognostic Index for early breast cancer: a systematic review and meta-analysis of observational studies | |
A systematic review of utility values for chemotherapy-related adverse events. | |
Toward health technology assessment of whole-genome sequencing diagnostic tests: challenges and solutions | |
Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key | |
TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’? | |
TPMT testing in rheumatology: any better than routine monitoring? | |
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. | |
Understanding Midwives' Preferences for Providing Information About Newborn Bloodspot Screening | |
Understanding the expectations of patients with inherited retinal dystrophies. | |
Use of a structured elicitation exercise to estimate the prevalence of OME in children with cleft palate. | |
Use of value of information in UK health technology assessments | |
Using a discrete choice experiment to elicit time trade-off and willingness-to-pay amounts for influenza health-related quality of life at different ages | |
Using Cost-Effectiveness Analysis to Quantify the Value of Genomic-Based Diagnostic Tests: Recommendations for Practice and Research | |
Using Discrete Choice Experiments to Inform the Benefit-Risk Assessment of Medicines: Are We Ready Yet? | |
Using qualitative methods for a conceptual analysis of measures of health status and presenteeism prior to a mapping study | |
Using the Payoff Time in Decision-Analytic Models: A Case Study for Using Statins in Primary Prevention | |
Utility Values for Adults with Unipolar Depression: Systematic Review and Meta-Analysis | |
The value of the managed entry of new drugs: a case study of donepezil | |
Valuing health across the lifespan: health state preferences for seasonal influenza illnesses in patients of different ages. | |
Valuing pharmacogenetic testing services: A comparison of patients' and health care professionals' preferences | |
Valuing Preferences for the Process and Outcomes of Clinical Genetics Services: A Pilot Study | |
Valuing the benefits of genetic testing for retinitis pigmentosa: a pilot application of the contingent valuation method | |
Valuing the economic benefits of complex interventions: when maximising health is not sufficient | |
Variation in healthcare services for specialist genetic testing and implications for planning genetic services: the example of inherited retinal dystrophy in the English NHS. | |
“I Was Trying to Do the Maths”: Exploring the Impact of Risk Communication in Discrete Choice Experiments | |
What process attributes of clinical genetics services could maximise patient benefits? | |
Which anaesthetic agents are cost-effective in day surgery? Literature review, national survey of practice and randomised controlled trial | |
Women’s preferences for the provision of emergency hormonal contraception services | |
'You don't get told anything, they don't do anything and nothing changes'. Medicine as a resource and constraint in progressive ataxia. |